Significantly Improved Nasal Congestion/Obstruction Score at
Weeks 24 (Coprimary Endpoint) and 52 (Key Secondary Endpoint) in Patients Who Were Uncontrolled on SOC1,2,a
SINUS-52
CHANGE IN NC SCORE THROUGH WEEK 52
IMPROVEMENT AT WEEK 24 with DUPIXENT Q2W + INCS (n=295, pooled DUPIXENT arms) (-1.25 from a baseline score of 2.46) vs 16% improvement with placebo + INCS (n=153) (-0.38 from a baseline score of 2.38) (LSM difference: -0.87 [95% CI: -1.03, -0.71]) in SINUS-521
- NC SCORE IMPROVED AS EARLY AS WEEK 4 IN SINUS-52: -0.52 with DUPIXENT Q2W + INCS (n=295, pooled DUPIXENT arms) vs -0.16 with placebo + INCS (n=153) (LSM difference: -0.37 [95% CI: -0.46, -0.27])1,2
IMPROVEMENT AT WEEK 24 with DUPIXENT Q2W + INCS (-1.34 from a baseline score of 2.26) vs 18% improvement with placebo + INCS (-0.45 from a baseline score of 2.45) (LSM difference: -0.89 [95% CI: -1.07, -0.71]) in SINUS-241
a All patients in the placebo and DUPIXENT arms were on a background therapy of INCS, mometasone furoate nasal spray.1
Nasal congestion/obstruction (NC) score (range 0 to 3): reduced score indicates improvement.
Administration
on DUPIXENT.